Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | BACE1 | P56817 | 3/20 | 0.74 |
| ▸ | SETD7 | Q8WTS6 | 5/20 | 0.62 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | ME2 | P23368 | 1/20 | 0.44 |
| ▸ | ME1 | P48163 | 1/20 | 0.44 |
| ▸ | ME3 | Q16798 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27169536 | 0.85 | HSD17B3 (0.78) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL12632648 | 0.82 | TDP1 (0.69) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL3786541 | 0.79 | KDM4E (0.66) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL28703413 | 0.78 | KDM4E (0.65) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL14433919 | 0.78 | SETD7 (0.64) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL25835140 | 0.78 | KDM4E (0.64) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL25834302 | 0.77 | HSD17B3 (0.67) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL11331344 | 0.76 | KDM4E (0.59) | MAPTKDM4EMEN1PKMMAPK1 | |
| SCHEMBL10959950 | 0.75 | HSD17B3 (1.00) | MAPTKDM4EMEN1PKMMAPK1 | |
| Ethane SCHEMBL28553030 | 0.75 | MAOA (0.91) | MAPTKDM4EMEN1PKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118176293-A | SIRPalpha-deficient macrophages for the treatment of cancer | 佐治亚州立大学研究基金会公司 | 2024-06-11 | — | — | CN | claimed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | claimed |
| WO-2023076813-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-115803092-A | SIRP alpha deficient macrophages for the treatment of cancer | 乔治亚州立大学研究基金公司 | 2023-03-14 | — | — | CN | claimed |
| EP-4139003-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2023-03-01 | — | — | EP | claimed |
| WO-2021217038-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-28 | — | — | WO | claimed |
| US-20250333698-A1 | SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER | UNIV GEORGIA STATE RES FOUND (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4423251-A1 | SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER | Georgia State University Research Foundation, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-118176293-A | SIRPalpha-deficient macrophages for the treatment of cancer | 佐治亚州立大学研究基金会公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | THE UNIVERSITY OF HONG KONG (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230220342-A1 | SIRPa Deficient Macrophages for Treating Cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| WO-2023076813-A1 | SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-115803092-A | SIRP alpha deficient macrophages for the treatment of cancer | 乔治亚州立大学研究基金公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-0222098-A2 | Water soluble triphenodioxazine compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-05-20 | — | — | EP | disclosed |
| US-4629788-A | COLORFASTNESS; BLUE COLOR; NATURAL AND SYNTHETIC FIBER | BAYER AKTIENGESELLSCHAFT (DE) | 1986-12-16 | — | — | US | disclosed |
| US-4621138-A | Triphendioxazine dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1986-11-04 | — | — | US | disclosed |
| US-4591643-A | Triphendioxazine reactive dyestuffs | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-27 | — | — | US | disclosed |
| EP-0158882-A2 | Triphenedioxazine dyes | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0144580-A2 | Triphendioxazine dyes | BAYER AG (DE) | 1985-06-19 | — | — | EP | disclosed |
| US-4016211-A | ARYLHYDROQUINONE STABILIZERS | SNAM PROGETTI S.P.A. (IT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227393-A1 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | NFE2L2, DUOX1, DUOX2 | MAPT 736/4885KDM4E 3115/4885MEN1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.